MedCity News August 7, 2024
G1 Therapeutics turned research from the University of North Carolina at Chapel Hill into novel cancer drug Cosela, which is approved in the U.S. and China. Pharmacosmos says its G1 acquisition will enable Cosela to reach more lung cancer patients around the world.
G1 Therapeutics steered a first-of-its-kind lung cancer drug to FDA approval, but long maintained that development and commercialization globally would require partnerships. There’s a new path forward for the drug, though it will be through an acquisition rather than a strategic alliance.
Pharmacosmos is acquiring G1 in a deal that values the Research Triangle Park, North Carolina-based biotech at $405 million, the companies announced Wednesday. Closely held Pharmacosmos, which is based in Denmark, has agreed to pay...
Today's Sponsors
Today's Sponsor